An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan

Bristol-Myers Squibb1 个研究点分布在 1 个国家开始时间: 2016年8月4日最近更新: 2023年12月19日

适应症

试验速览

阶段: 不适用
状态: No Longer Available
发起方
试验地点: 1

研究概览入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at Japanese sites where licensed physicians determine clinical need.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 20 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

No Longer Available

不适用

Expanded Access Treatment Protocol CA204-143Multiple Myeloma

NCT02368301Bristol-Myers Squibb

No Longer Available

不适用

Flotetuzumab Expanded Access ProgramAcute Myeloid LeukemiaAML, Adult RecurrentAML

NCT04678466MacroGenics

No Longer Available

不适用

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple Sclerosis

NCT02807285Genentech, Inc.

未知

Unknown

Early Patient Access Treatment Use Protocol CA204-220relapsed or refractory multiple myeloma

JPRN-jRCT2080223322Bristol-Myers Squibb K.K.

Temporarily Not Available

不适用

Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)

NCT04830202AbbVie